Replimune announced FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 10 to 3 that the efficacy results from the Ignyte study are evaluable and clinically meaningful. Following FDA’s announcement backing the results, the company’s stock nearly doubled, surging over 120%.3How did the application get to this point? We look forward to continuing to work with the FDA as it completes its review of the BLA ahead of the action date." We look forward to continuing to work with the FDA as it completes its review of the BLA ahead of the action date." What is the Ignyte study?